Biotech And CAR-T Research In China

The clinical trial landscape is increasingly costly and competitive, especially in the biotechnology industry. Smaller companies need help finding funding opportunities and competing with larger companies for participants and resources, especially in the U.S. and Europe. More companies are turning to the Asia-Pacific (APAC) region, which has a high population but is underutilized in global clinical trials. China’s trial density is six times lower than the U.S. and five times lower than Europe. However, its cell-and-gene therapy research has a compound annual growth rate of 18%, higher than any other country. China’s high population, low trial density, and investment in biotech make it an ideal location for clinical trials. Additionally, its CAR-T research is paving the way for innovative treatments for non-Hodgkin’s lymphoma and other cancers.

Dr. Vivian Gu, Head of CDR, China CMO, Novotech PPC; Dr. Kai Xue, Professor, Fudan University, Shanghai Cancer Center; and Dr. Jie Chen, Chief Medical Officer, Bioheng recently hosted a webinar highlighting China’s growing biotech industry and CAR-T therapy. Download the full article to review the Q&A session held after the event, where the presenters addressed attendee questions about biotech research in China.